Key clinical point: Tildrakizumab showed durable high efficacy and reassuring safety for psoriasis over the course of 5 years of follow-up.
Major finding: Eighty-nine percent of psoriasis patients with a PASI-75 response to tildrakizumab at week 28 of a long-term extension study maintained that response throughout the next 4½ years of treatment.
Study details: This was a long-term extension study including 622 tildrakizumab-treated participants in the short-term, pivotal, phase-3 reSURFACE 1 and reSURFACE 2 randomized trials.
Disclosures: The presenter reported serving as an adviser to and paid investigator for Almirall, the study sponsor, and numerous other pharmaceutical companies.
FROM THE EADV CONGRESS